<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763658</url>
  </required_header>
  <id_info>
    <org_study_id>Antioxident in ITP</org_study_id>
    <nct_id>NCT01763658</nct_id>
  </id_info>
  <brief_title>Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia</brief_title>
  <acronym>ITP</acronym>
  <official_title>Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxidative stress occurs as a result of increased activity of free radical-producing enzymes,
      decreased activity of free radical-removing enzymes, and insufficient levels of antioxidants.
      The most sensitive molecules to oxidation are lipids. Loss of cell membrane elasticity,
      increased cell fragility, and a shortened cellular life span results from oxidation of cell
      membrane lipids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Free oxygen radicals may have an effect on the structural and functional damage of platelets
      and plays a role in pathogenesis of thrombocytopenia in both, acute and chronic ITP.

      Selenium is an essential mineral found in small amounts in the body. It works as an
      antioxidant, especially when combined with other antioxidants as vitamin E , A and C.
      Antioxidants neutralize free radicals and may reduce or even help prevent some of the damage
      they cause.

      aim of this study is to assess oxidant and antioxidant systems initially in patients with
      acute and chronic immune thrombocytopenia (ITP) and 6 months later.Another aim of the study
      is to evaluate effect of antioxidant therapy on bleeding score, platelet count and
      antioxidant status during 6 months follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxidant status in ITP</measure>
    <time_frame>6 month</time_frame>
    <description>oxidant and antioxidant systems initially in patients with acute and chronic immune thrombocytopenia (ITP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>antioxidant therapy</measure>
    <time_frame>6 months</time_frame>
    <description>antioxidant therapy on bleeding score, platelet count and antioxidant status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Antioxidant, drug therapy for ITP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug therapy for ITP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drug therapy for ITP according to ASH, 2011 guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antox tablets(Mepaco)</intervention_name>
    <description>effect of antioxidant on disease outcome</description>
    <arm_group_label>Antioxidant, drug therapy for ITP</arm_group_label>
    <other_name>antioxidant drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>drug therapy for ITP</intervention_name>
    <description>drugs will be selected according to ASH,2011 guidelines</description>
    <arm_group_label>Antioxidant, drug therapy for ITP</arm_group_label>
    <arm_group_label>drug therapy for ITP</arm_group_label>
    <other_name>dexamethasone</other_name>
    <other_name>prednisolone</other_name>
    <other_name>solumedrol</other_name>
    <other_name>Anti-D</other_name>
    <other_name>intravenous immunoglobulin</other_name>
    <other_name>romioplastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. All patients less than 18 years with primary ITP; at initial presentation with
             platelet count less than 40 x 109/L attended Ain Shams Hematology clinic Children
             hospital from January 2013 and followed-up for 6 months.

             2. For acute ITP, patients will be newly diagnosed (about one month within the
             diagnosis).

             3. For chronic (12-24 months) and persistent (3-12 months) ITP patients.

        Exclusion Criteria:

          1. Patients' platelet count more than 40 x 109/L.; or above 18 years

          2. Patients with secondary cause for thrombocytopenia.

          3. Patients with any there associated chronic illness affecting oxidant status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohsen S Elalfy, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yasmine I Elhenawy, lecturer</last_name>
    <phone>0104084038</phone>
    <email>dr_yasmi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>hematology clinic ,pediatrics hospital, Ain Shams University hospital Cairo, Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohsen Saleh Elalfy, professor</last_name>
    </contact>
    <investigator>
      <last_name>Mohsen Saleh Elalfy, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohsen Saleh Elalfy</investigator_full_name>
    <investigator_title>professor of pediatrics</investigator_title>
  </responsible_party>
  <keyword>ITP, antioxidant therapy, oxidant status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

